News

The data showed that the new regulatory elements can distinguish the estrogenic pharmacological activity exerted by different compounds and allow for more accurate prediction of specific tissue effect.

Under the companies’ collaboration agreement, Curis will receive a $6 million cash payment from Genentech following initiation of this pivotal trial. Genentech expects to evaluate GDC-0449 in approximately

In the first Phase II trial, DM-71 showed statistically significant declines in HbA1c, fructosamine and weight with an excellent safety profile in humans, the company said. This second

Lilly said that it has been co-operating with the government in its investigation since it began in 2004. As part of the resolution, Lilly has agreed to plead

Operating revenue was $3.71 billion, a 25% increase from $2.97 billion in the fourth quarter of 2007. US product sales for the fourth quarter of 2008 were $2.5

In December 2006, Halozyme entered into an agreement with Roche to apply Halozyme’s Enhanze technology to Roche’s biological therapeutic compounds. Under the terms of the agreement, Roche paid

This is the second licensing agreement between the two companies concerning Merrion’s Gipet technology – the first agreement for the development of oral insulin analogs was signed in

In his most recent endeavor, Faulkner served as president, chief executive officer (CEO) and member of the board of directors of Digene Corporation, a Nasdaq-traded company prior to

“The opportunity that lies in front of Abraxis BioScience is enormous and is a result of the validated science underlying the company’s proprietary nab(R) technology in the clinical